The accuracy and robustness of plasma biomarker models for amyloid PET positivity

BACKGROUND: Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) pathology to support trial recruitment or initiating Aβ-targeting treatments would be of critical value. In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedet, Andréa L., Brum, Wagner S., Hansson, Oskar, Karikari, Thomas K., Zimmer, Eduardo R., Zetterberg, Henrik, Blennow, Kaj, Ashton, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819863/
https://www.ncbi.nlm.nih.gov/pubmed/35130933
http://dx.doi.org/10.1186/s13195-021-00942-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819863/
https://www.ncbi.nlm.nih.gov/pubmed/35130933
http://dx.doi.org/10.1186/s13195-021-00942-0

Ejemplares similares